Microdosing GLP-1 refers to taking GLP-1 medications like semaglutide or tirzepatide at a fraction of the FDA-approved dose, often to save money or reduce side effects. The practice has gained traction on social media, but it carries real risks, particularly when done without medical supervision or with compounded (non-brand) versions of these drugs.
How Microdosing Differs From Standard Dosing
GLP-1 medications are designed to be taken on a specific schedule, typically starting at a low dose that gradually increases over several weeks. Semaglutide, for example, starts at 0.25 mg weekly and ramps up to higher maintenance doses. This slow titration is itself a kind of low-dose phase, built into the prescribing guidelines to help your body adjust.
Microdosing goes further. It means staying at doses well below the approved range, sometimes indefinitely, or using fractional “clicks” from multidose pen devices to deliver amounts smaller than any labeled dose. Some people use compounded semaglutide from vials, drawing up tiny amounts with insulin syringes. The goal is usually one of two things: spending less money on the medication, or avoiding the nausea, vomiting, and other GI symptoms that are common at standard doses.
Why People Are Drawn to It
Cost is a major driver. Brand-name GLP-1 medications can be expensive, and not everyone has insurance coverage for them. Compounded versions sold by telehealth companies and online pharmacies were, for a time, significantly cheaper. That price gap has narrowed, though. Manufacturer discounts now often make brand-name medications comparable in cost to compounded alternatives, or even less expensive.
Side effects are the other big motivator. GLP-1 drugs commonly cause nausea, vomiting, diarrhea, and constipation, especially during dose increases. The logic behind microdosing is straightforward: a smaller dose should mean milder side effects. For some people, particularly those who are highly sensitive to medications, this reasoning has appeal. And in clinical settings, some physicians do intentionally keep patients on lower doses if they respond well or can’t tolerate higher ones. But that’s a supervised, individualized decision, not the same as self-adjusting doses at home based on social media advice.
What Clinicians Actually Do With Lower Doses
There’s an important distinction between the microdosing trend and legitimate medical practice. Some obesity medicine specialists keep patients on lower-than-maximum doses when it makes clinical sense. This happens when a patient is highly sensitive to side effects, when they achieve meaningful metabolic improvements at a lower level, or when they’re transitioning off the medication. This is individualized medical decision-making guided by lab work, body composition data, and ongoing monitoring.
A small study from Scripps Clinic looked at a related concept: reducing how often patients took their GLP-1 medication rather than lowering the dose itself. In that retrospective study of 30 patients, most participants maintained their peak weight loss even after moving from weekly injections to once every two weeks, and some stretched to once every six weeks. The researchers were careful to note that this reduced-frequency approach is not the same as the microdosing trend popularized on social media, and that all medications should be taken as prescribed.
The Dosing Error Problem
One of the most concrete dangers of microdosing, especially with compounded vials, is getting the dose wrong. The FDA has flagged multiple cases of serious dosing errors with compounded injectable semaglutide. The core problem is confusion between units of measurement. Compounded products often come in vials that require you to draw medication into a syringe, and the instructions (if provided at all) may list doses in “units” rather than milligrams or milliliters. The volume per “unit” can vary depending on the concentration of the specific product.
The results have been alarming. In one reported case, a provider intended to prescribe 0.25 milligrams (5 units) but wrote 25 units instead, giving the patient five times the intended dose and causing severe vomiting. In another, a provider prescribed 20 units instead of 2, and three patients received ten times the intended amount. Even a patient who was themselves a healthcare provider miscalculated their own dose and injected ten times more than planned. These aren’t theoretical risks. They are documented incidents reported to the FDA.
FDA Enforcement and Compounded Products
The FDA has taken an increasingly aggressive stance against compounded GLP-1 products. In 2025, the agency announced its intent to restrict GLP-1 active ingredients used in non-FDA-approved compounded drugs that are mass-marketed as alternatives to branded medications. The announcement specifically named companies like Hims & Hers and other compounding pharmacies.
The agency’s concerns center on the fact that it cannot verify the quality, safety, or efficacy of compounded products. Companies are prohibited from claiming that compounded products are generic versions of FDA-approved drugs, that they use the same active ingredient, or that they are “clinically proven” to produce results. The FDA has warned that it will pursue seizure and legal injunctions against entities that continue marketing unapproved compounded GLP-1 products.
This matters for microdosing because many people who microdose are doing so with compounded products, which are the versions most accessible without traditional prescriptions and most prone to the dosing errors described above.
Does Microdosing Actually Work for Weight Loss?
This is where the evidence gets thin. There are no published clinical trials specifically testing microdosing regimens for weight loss. The weight loss data that exists for semaglutide and tirzepatide comes from trials using standard, FDA-approved dose ranges. Lower doses within those approved ranges do produce less weight loss than higher doses, which is why the medications are designed to be titrated upward.
Taking a fraction of the starting dose puts you well below any dose that’s been formally studied. You might experience some appetite suppression, but there’s no reliable data on how much weight loss to expect, how long any effect lasts, or whether the metabolic benefits (like improved blood sugar control and cardiovascular protection) are preserved at very low doses. You’re essentially running an experiment on yourself without a control group.
Who Might Benefit From a Lower Dose
For a smaller group of patients, a carefully monitored lower dose can be a reasonable option, but only when guided by a clinician who can track your response. This typically applies to people who have already lost weight on standard doses and are looking to maintain it with less medication, people who experience side effects severe enough to make standard titration impractical, or people whose metabolic markers improve meaningfully before reaching the full maintenance dose.
For everyone else, the standard prescribing approach exists for a reason. The titration schedule was designed through clinical trials to balance effectiveness with tolerability. Skipping that process to save money or avoid discomfort may mean you get neither the weight loss nor the metabolic benefits the medication is capable of providing, while still exposing yourself to risks from an unregulated product or an imprecise dose.